Clinical Trial Update: Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2 [Phase 2]

View source ↗

Summary

Phase II safety and tolerability trial evaluating nab-paclitaxel plus carboplatin followed by nab-paclitaxel as first-line treatment in non-small cell lung canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Celgene | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2018-04-24